(Q38255333)

1 September 2017

1 reference

title

Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back (English)

1 reference

1 September 2017

1 reference

Giada Bianchi

1 reference

1 September 2017

Kenneth C Anderson

series ordinal

1 reference

1 September 2017

language of work or name

English

0 references

publication date

29 September 2014

1 reference

1 September 2017

1 reference

1 September 2017

1 reference

1 September 2017

1 reference

1 September 2017

page(s)

422-444

1 reference

1 September 2017

cites work

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Paraproteins of familial MGUS/multiple myeloma target family-typical antigens: hyperphosphorylation of autoantigens is a consistent finding in familial and sporadic MGUS/MM

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

21 January 2018

Pathogenesis of Myeloma

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Long-lived plasma cells in immunity and inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

A monoclonal gammopathy precedes multiple myeloma in most patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Diagnosis of Smoldering Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Genomic instability in multiple myeloma: mechanisms and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

IRF4 addiction in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

The genetic architecture of multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Initial genome sequencing and analysis of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Hyperviscosity syndrome in multiple myeloma. A reversible, concentration-dependent aggregation of the myeloma protein

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Plasma Cell Myeloma and Related Neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

The role of whole-body imaging in the diagnosis, staging, and follow-up of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Molecular Imaging in Myeloma Precursor Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

International staging system for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

21 January 2018

Ultra high-risk myeloma

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-r

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Is the International Staging System superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Improved survival in multiple myeloma and the impact of novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

How we manage autologous stem cell transplantation for patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995-2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

International uniform response criteria for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Single versus double autologous stem-cell transplantation for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

How I treat multiple myeloma in younger patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Best treatment strategies in high-risk multiple myeloma: navigating a gray area

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Novel agents for multiple myeloma to overcome resistance in phase III clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Multiple myeloma bone marrow niche

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Lenalidomide mode of action: linking bench and clinical findings

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Identification of a primary target of thalidomide teratogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

The development of proteasome inhibitors as anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Functions of the proteasome: the lysis at the end of the tunnel

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Getting to first base in proteasome assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Mechanisms of proteasome inhibitor action and resistance in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

IMWG consensus on maintenance therapy in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Comparison of twin and autologous transplants for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

The unfolded protein response: from stress pathway to homeostatic regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Proteostenosis and plasma cell pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Breaking the chains: structure and function of the deubiquitinases

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Deubiquitinases in cancer: new functions and therapeutic options.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Molecular chaperones in protein folding and proteostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Inhibition of HSP90 molecular chaperones: moving into the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

BET bromodomain inhibition as a therapeutic strategy to target c-Myc

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Evolution of cellular immunotherapy: from allogeneic transplant to dendritic cell vaccination as treatment for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Osteonecrosis of the jaw and bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI)

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21252

21 January 2018

Identifiers

DOI

10.3322/CAAC.21252

1 reference

1 September 2017

1 reference